| Mr Gregory G Hamrick, CRNP | |
|
701 University Blvd E, Suite 400, Tuscaloosa, AL 35401 | |
| (205) 752-0694 | |
| (205) 752-6244 |
| Full Name | Mr Gregory G Hamrick |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 25 Years |
| Location | 701 University Blvd E, Tuscaloosa, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063476679 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 1-042184 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cardiology Consultants Pc | 9739143926 | 12 |
News Archive
Dr Bock, under the mentorship of Distinguished Professor Dietmar Hutmacher, from QUT Centre for Biomedical Technologies, has focused her research on bone metastases from breast and prostate cancers.
Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company out of India, today announced the repayment of FCCBs amounting to US$ 50 million along with the YTM of US$ 19 million. The FCCBs were due for redemption on May 24, 2010.
A recent study funded by Centers for Disease Control and Prevention Epicenters Program and published in Infection Control and Hospital Epidemiology ( Deverick H. Anderson , M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. – some of the common culprits of health care-associated infections drawing increased attention for hospitals across the country.
The quality of the emotional relationship between a mother and her young child could affect the potential for that child to be obese during adolescence, a new study suggests.
The U.S. Food and Drug Administration today approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years. Prevnar 13 will be the successor to Prevnar, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in 2000 to prevent invasive pneumococcal disease (IPD) and otitis media. The new vaccine extends the protection to six additional types of the disease causing bacteria.
› Verified 3 days ago
| Entity Name | Cardiology Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548224157 PECOS PAC ID: 9739143926 Enrollment ID: O20041117000544 |
News Archive
Dr Bock, under the mentorship of Distinguished Professor Dietmar Hutmacher, from QUT Centre for Biomedical Technologies, has focused her research on bone metastases from breast and prostate cancers.
Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company out of India, today announced the repayment of FCCBs amounting to US$ 50 million along with the YTM of US$ 19 million. The FCCBs were due for redemption on May 24, 2010.
A recent study funded by Centers for Disease Control and Prevention Epicenters Program and published in Infection Control and Hospital Epidemiology ( Deverick H. Anderson , M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. – some of the common culprits of health care-associated infections drawing increased attention for hospitals across the country.
The quality of the emotional relationship between a mother and her young child could affect the potential for that child to be obese during adolescence, a new study suggests.
The U.S. Food and Drug Administration today approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years. Prevnar 13 will be the successor to Prevnar, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in 2000 to prevent invasive pneumococcal disease (IPD) and otitis media. The new vaccine extends the protection to six additional types of the disease causing bacteria.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Gregory G Hamrick, CRNP 701 University Blvd E, Suite 400, Tuscaloosa, AL 35401 Ph: (205) 752-0694 | Mr Gregory G Hamrick, CRNP 701 University Blvd E, Suite 400, Tuscaloosa, AL 35401 Ph: (205) 752-0694 |
News Archive
Dr Bock, under the mentorship of Distinguished Professor Dietmar Hutmacher, from QUT Centre for Biomedical Technologies, has focused her research on bone metastases from breast and prostate cancers.
Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company out of India, today announced the repayment of FCCBs amounting to US$ 50 million along with the YTM of US$ 19 million. The FCCBs were due for redemption on May 24, 2010.
A recent study funded by Centers for Disease Control and Prevention Epicenters Program and published in Infection Control and Hospital Epidemiology ( Deverick H. Anderson , M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. – some of the common culprits of health care-associated infections drawing increased attention for hospitals across the country.
The quality of the emotional relationship between a mother and her young child could affect the potential for that child to be obese during adolescence, a new study suggests.
The U.S. Food and Drug Administration today approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years. Prevnar 13 will be the successor to Prevnar, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in 2000 to prevent invasive pneumococcal disease (IPD) and otitis media. The new vaccine extends the protection to six additional types of the disease causing bacteria.
› Verified 3 days ago
Ms. Sarah Oliver Pate, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2731 Mlk Jr. Blvd, Tuscaloosa, AL 35401 Phone: 205-349-3250 Fax: 205-345-3993 | |
Mrs. Haley Patrick Hill, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 100 Rice Mine Road, Suite B, Tuscaloosa, AL 35406 Phone: 205-349-4200 | |
Doris D Patton, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3701 Loop Rd, Tuscaloosa, AL 35404 Phone: 205-554-2000 | |
Casey Elizabeth Jones, RN, MSN, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1651 Ruby Tyler Pkwy, Tuscaloosa, AL 35404 Phone: 205-507-8930 | |
Caleb Elmore, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 701 University Blvd E Ste 400, Tuscaloosa, AL 35401 Phone: 205-752-0694 Fax: 205-752-6244 | |
Holly K. Freeman, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 100 Towncenter Blvd, Ste 300, Tuscaloosa, AL 35406 Phone: 205-710-3838 Fax: 205-710-3839 | |
Alice Mae Cunningham, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 200 University Blvd, Bryce Hospital, Tuscaloosa, AL 35401 Phone: 205-759-0799 Fax: 205-759-0845 |